HETLIOZ
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 15 Oct 2026)
What this means for you
Registered since 03 Aug 2021. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 03 Aug 2031: the §8 & §9 renewal).
Record
- Serial number
- 88981892
- Registration number
- 6442600
- Mark type
- Word mark
- Filed
- 01 Apr 2019
- Published for opposition
- 17 Dec 2019
- Registered
- 03 Aug 2021
- Next maintenance filing
- §8 & §9 renewal, due by 03 Aug 2031 (grace period to 03 Feb 2032)
- Attorney of record
- Jayme M. Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, containing tasimelteon, for use in the treatment of circadian rhythm diseases and disorders; pharmaceutical preparations, containing tasimelteon, for use in the treatment of non-24 hour sleep-wake disorder; and pharmaceutical preparations containing tasimelteon for use in the treatment of circadian rhythm sleep disorders; pharmaceutical preparations containing tasimelteon for use in the treatment of Smith-Magenis Syndrome
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prior registrations
Prosecution history
- 15 Oct 2026 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 15 Oct 2026 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 15 Oct 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 05 Aug 2026 — TEAS SECTION 8 & 15 RECEIVED
- 03 Aug 2026 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 03 Aug 2021 — REGISTERED-PRINCIPAL REGISTER
- 26 Jun 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 25 Jun 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 03 Jun 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 25 Jan 2021 — USE AMENDMENT FILED
- 03 Jun 2021 — DIVISIONAL PROCESSING COMPLETE
- 25 Jan 2021 — DIVISIONAL REQUEST RECEIVED
- 01 Jun 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 10 Feb 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 25 Jan 2021 — TEAS REQUEST TO DIVIDE RECEIVED